Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Burdened by continuing troublesome inflation and cuts to federal health agencies, health care sector stocks are barely treading water. The S&P 500 Health Care Sector Index was fla ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

F M Investments boosted its stake in Regeneron Pharmaceuticals by 8.5% in Q4, grabbing 7,003 shares worth nearly $5 million.

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Cerity Partners gave Regeneron a small but mighty vote of confidence, upping their stake by 3.3% in the fourth quarter. They ...